萍萍家园's Archiver

lazyboy_1 发表于 2012-3-21 14:13

求Future Oncol文献一篇

【题名】:Abiraterone acetate:a promising drug for the treatment of castration-resistant prostate cancer
【作者】:Agarwal N, Hutson TE, Vogelzang NJ, Sonpavde G.
【杂志名全称】:Future Oncol
【年, 卷(期), 起止页码】: 2010 May;6(5):665-79
【DOI】:10.2217/fon.10.48
【全文链接】:[url]http://www.futuremedicine.com/doi/abs/10.2217/fon.10.48[/url]
【摘要信息】:Abiraterone acetate (CB7630), a pregnenolone analog, is an orally administered small molecule

that irreversibly inhibits a rate-limiting enzyme in androgen biosynthesis, CYP17, and blocks the

synthesis of androgens in the testes, adrenal glands and prostate without causing adrenal

insufficiency. In clinical studies, abiraterone acetate is well tolerated and shows promising clinical

activity in castration-resistant prostate cancer. The recommended Phase II dose of abiraterone

acetate is 1000 mg orally daily in combination with prednisone 5 mg twice daily. Side effects are

minimal and mostly associated with secondary mineralocorticoid excess, owing to a

compensatory increase in upstream steroids, such as deoxycorticosterone and corticosterone.

These include hypertension, hypokalemia and edema and are easily manageable with a selective

mineralocorticoid antagonist, such as eplerenone, or low-dose corticosteroids. Currently,

abiraterone acetate is being tested in a Phase III trial for men with progressive castration-resistant

prostate cancer who are chemotherapy naive. A Phase III trial for patients following prior

chemotherapy has been completed and is awaiting analysis
【求助者email】:[email]yongliangliu@foxmail.com[/email]

注:求助格式请按上面的要求逐项填写,尤其是全文链接。
     求助标题请用期刊缩写。
(重要!!)为提高应助速度,最好给出文献简要摘要信息,方便大家。

casaries 发表于 2012-3-21 14:13

[url]http://115.com/file/e7bexnwo#fon.10.48.pdf[/url]

页: [1]

Powered by Discuz! Archiver 7.2  © 2001-2009 Comsenz Inc.